Advertisement
IDXX vs MLSS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a Hold and MLSS is a Hold.
IDXX's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for IDXX moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 26 of the 33 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 57 cases where IDXX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for IDXX just turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 26 of 42 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 176 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDXX as a result. In 67 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.840) is normal, around the industry mean (72.578). P/E Ratio (37.179) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
IDXX | MLSS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 16 | 99 | |
PRICE GROWTH RATING 1..100 | 57 | 63 | |
P/E GROWTH RATING 1..100 | 75 | 100 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDXX's Valuation (70) in the Medical Specialties industry is in the same range as MLSS (96). This means that IDXX’s stock grew similarly to MLSS’s over the last 12 months.
IDXX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MLSS (100). This means that IDXX’s stock grew similarly to MLSS’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is significantly better than the same rating for MLSS (99). This means that IDXX’s stock grew significantly faster than MLSS’s over the last 12 months.
IDXX's Price Growth Rating (57) in the Medical Specialties industry is in the same range as MLSS (63). This means that IDXX’s stock grew similarly to MLSS’s over the last 12 months.
IDXX's P/E Growth Rating (75) in the Medical Specialties industry is in the same range as MLSS (100). This means that IDXX’s stock grew similarly to MLSS’s over the last 12 months.
| IDXX | MLSS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 62% | N/A |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 60% | 8 days ago 79% |
| Declines ODDS (%) | 8 days ago 69% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green while MLSS’s FA Score has 0 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- MLSS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 4 TA indicator(s) are bullish while MLSS’s TA Score has 4 bullish TA indicator(s).
- IDXX’s TA Score: 4 bullish, 4 bearish.
- MLSS’s TA Score: 4 bullish, 5 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а +0.95% price change this week, while MLSS (@Pharmaceuticals: Other) price change was -7.38% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.57%. For the same industry, the average monthly price growth was +1.42%, and the average quarterly price growth was +38.10%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.14%, and the average quarterly price growth was +7.32%.
Reported Earning Dates
IDXX is expected to report earnings on Nov 02, 2026.
MLSS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Medical Specialties (-3.57% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-1.23% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | -0.69% | ||
| ALGN - IDXX | 50% Loosely correlated | +2.22% | ||
| SYK - IDXX | 48% Loosely correlated | -0.02% | ||
| SHC - IDXX | 45% Loosely correlated | +0.33% | ||
| BLCO - IDXX | 45% Loosely correlated | -1.62% | ||
| SNN - IDXX | 44% Loosely correlated | +0.69% | ||
More | ||||
MLSS and
Correlation & Price change
A.I.dvisor tells us that MLSS and ANGO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and ANGO's prices will move in lockstep.
| Ticker / NAME | Correlation To MLSS | 1D Price Change % | ||
|---|---|---|---|---|
| MLSS | 100% | -2.30% | ||
| ANGO - MLSS | 29% Poorly correlated | -4.39% | ||
| ESTA - MLSS | 26% Poorly correlated | -5.16% | ||
| QDEL - MLSS | 25% Poorly correlated | +6.42% | ||
| GKOS - MLSS | 25% Poorly correlated | -1.50% | ||
| IDXX - MLSS | 25% Poorly correlated | -0.69% | ||
More | ||||